INTRODUCTION
Lung cancer is the leading cause of cancer-related death worldwide. 1 Non-small-cell lung cancer (NSCLC) accounts for almost 85% of all lung cancers, and adenocarcinoma is the most common type of NSCLC. 2 The development of therapeutics targeting epidermal growth factor receptor (EGFR) tyrosine kinase has been one of the great clinical advances in NSCLC, especially in adenocarcinoma.
Both gefitinib and erlotinib have anilinoquinazoline structure, bind reversely to the ATP binding pocket of the EGFR, and are referred to as first-generation EGFR tyrosine kinase inhibitors (TKIs). The recommended and maximum tolerated dosages are the same for erlotinib (150 mg/d), whereas the maximum tolerated dose of gefitinib is almost three-fold that of its standard recommended dosage of (250 mg/d).
that several types of somatic mutations in the tyrosine kinase domain of the EGFR gene display a response to EGFR-TKI agents, with some investigators reporting this mutation to be a predictor for response to EGFR-TKIs. 5, 6 EGFR-TKIs are now a mainstay in the treatment of EGFR mutation-positive NSCLC, although for a fairly long time, they were used according to the clinical background of the patient with NSCLC.
A phase II trial of gefitinib IDEAL1 3 (Iressa Dose Evaluation in Advanced Lung Cancer) showed the response rate (RR) in the Japanese subset to be 27.5%, which was higher than the RR among non-Japanese patients. As a result of these data, gefitinib was approved in 2002 in Japan for use as second-line treatment and beyond. Four years later, gefitinib failed to display superiority over best supportive care (BSC) in previously treated patients with NSCLC in a large phase III trial-ISEL (Iressa Survival Evaluation in Lung Cancer); the median overall survival (OS), 5.6 months for gefitinib v 5.1 months for BSC; hazard ratio (HR), 0.89; P = .087. 7 In contrast to gefitinib, in the BR.21 trial, 8 a randomized phase III trial of erlotinib versus placebo in previously treated patients with NSCLC, erlotinib extended survival (median OS, 6.7 months for erlotinib v 4.7 months for BSC; HR, 0.70; P = .001). Erlotinib was subsequently also approved in Japan in 2007. When our study was being planned, both of these drugs were available in Japan in the normal clinical setting for use as second-line and beyond treatment, and EGFR mutation inspections were not widespread in Japan. There had been no prospective phase III studies directly comparing gefitinib to erlotinib in the treatment of advanced lung adenocarcinoma. Therefore, we designed a multicenter randomized phase III study to demonstrate the noninferiority of gefitinib compared with erlotinib.
PATIENTS AND METHODS

Patient Selection
Patients were considered eligible if they met the following criteria: histologically or cytologically proven adenocarcinoma with stage IIIB or IV disease (American Joint Committee on Cancer version 6) or postoperative recurrence; previous treatment with at least one chemotherapy regimen; EGFR-TKI treatment naïve; evaluable disease lesions; age $ 20 years; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2; and adequate organ function. The exclusion criteria were as follows: radiographic evidence of interstitial pneumonia or pulmonary fibrosis on chest computed tomography (CT), radiation therapy on the mediastinum or lung field within the past 2 weeks, massive or uncontrolled pleural/pericardial effusion or ascites, presence of active infection, watery diarrhea, intestinal paralysis or ileus, symptomatic brain metastasis, active double cancer, unable to swallow oral medication, serious cardiac disease, serious psychiatric disorder, pregnancy, or judged to be inappropriate by the attending doctor. Protocol amendments were made in December 2011 because the Pharmaceuticals and Medical Devices Agency in Japan limited the use of gefitinib to patients harboring EGFR mutations. This resulted in only patients with EGFR mutations being enrolled in the study. All enrolled patients provided written informed consent to participate and the study protocol was approved by the West Japan Oncology Group Protocol Review Committee and the review board of each participating institution.
Treatment Plan
Patients were randomly assigned in a 1:1 ratio to receive either erlotinib (150 mg/d) or gefitinib (250 mg/d) by a centralized dynamic random assignment method using the following factors: sex, stage, EGFR mutation status, ECOG PS, smoking history, line of chemotherapy, and institution. Treatment was continued until progression of disease or development of intolerable toxicities or a request by the patient or physician to discontinue treatment. The erlotinib dosage could be reduced to 100 mg and 50 mg, and the gefitinib dosage could be reduced to 250 mg on alternate days and 250 mg once every 3 days to reduce toxic effects.
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End Points
The primary end point of this open-labeled, multicenter, randomized phase III trial was progression-free survival (PFS), which was assessed by investigators to establish the noninferiority of gefitinib to erlotinib. The secondary end points (Appendix, online only) included OS, investigatorassessed RR, disease control rate (DCR), safety, and time to treatment failure (TTF).
Evaluation
The baseline evaluation consisted of a complete medical history and physical examination, ECG, ECOG PS, CBC, blood chemistry, blood gas analysis, CT scan of the chest and abdomen, magnetic resonance imaging or CT of the brain, and bone scintigraphy or positron emission tomography scan. According to the study protocol, during treatment, patients underwent a CT scan of the chest and upper abdomen every 4 weeks and a CT or magnetic resonance imaging scan of the brain after 3 to 6 months and upon symptoms related to brain metastasis. All responses were defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. We used a random sampling method to sample one third of the patients. External reviews of their PFS and response were performed using CT film by experts who were not aware of the treatment assignments. Toxicity was evaluated according to the Common Terminology Criteria for Adverse Events (version 3.0).
Study Design and Statistical Analysis
The primary end point of this study, PFS, was analyzed in the fullanalysis set (FAS) population by estimation of the HR and two-sided 95% CIs derived from a Cox regression model with adjustment for the random assignment factors except for investigator center. The FAS patient population included all enrolled patients and excluded patients who did not meet the inclusion criteria for this study after enrollment and were, therefore, ineligible for inclusion in the analysis. The safety population was defined as all patients who received study medication at least once.
This trial was designed to demonstrate noninferiority of gefitinib compared with erlotinib with a noninferiority margin of 1.30 in terms of the adjusted HR. That is, the noninferiority was to be concluded if the upper limit of the 95% CI of the adjusted HR was less than 1.30. Assuming a median PFS of 4 months in both treatment arms with 1 year of follow-up after 3.5 years of accrual, 268 patients were required in each treatment group to show noninferiority with an 80% statistical power at a two-sided significance level of P = .05. The sample size was set at 560 patients (280 patients per arm) in consideration for potential dropouts.
No interim analysis was planned. Survival curves (PFS, OS, and TTF) were analyzed by the Kaplan Meier method and were compared between groups by the Cox regression model and log-rank test. The 95% CIs for median PFS, OS, and TTF were calculated using the Brookmeyer and Crowley method. Planned subgroup analyses for PFS were performed to examine the interaction effect of treatment arm with each of the following factors: sex, clinical stage, ECOG PS, smoking status, and EGFR mutation status. Patient characteristics (ie, age, ECOG PS, sex, clinical stage, prior treatment, EGFR mutation status, and smoking status) and tumor response were compared between the two treatment arms using the x 2 test.
Toxicity incidence was compared using Fisher's exact test. All P values were two-sided. Statistical analyses were performed using SAS for Windows, release 9.3 (SAS Institute, Cary, NC).
RESULTS
Patients
From July 2009 to October 2012, 561 patients were enrolled from 63 hospitals in Japan (Fig 1) . Two patients with no prior chemotherapy (one patient in each arm) were excluded from final analysis; thus, 280 and 279 patients were randomly assigned to gefitinib and erlotinib, respectively, in the FAS, with approximately 70% of patients being EGFR mutation-positive. Baseline characteristics (Table 1) , except PS, were well balanced between the treatment arms. Five hundred fifty-three patients who received study treatment (gefitinib, n = 277; erlotinib, n = 276) were assessable for toxicity analysis. At the cutoff date for collection of data (October 28, 2013), 10.4% of the patients in each arm were continuing to receive the study treatment. The most common reason for incompletion of the protocol treatment was disease progression, and no dissociation was seen in either arm. Thirtythree and 32 patients in the gefitinib and erlotinib arms, respectively, had treatment discontinued as a result of toxicity. Median follow-up times for gefitinib and erlotinib were 25.1 months (95% CI, 22.1 to 30.1 months) and 26.5 months (95% CI, 21.9 to 35.1 months), respectively.
Efficacy
Median PFS, TTF, and OS time for gefitinib versus erlotinib in the FAS were 6.5 and 7.5 months (adjusted HR, 1.125; 95% CI, 0.940 to 1.347; and unadjusted HR, 1.068; 95% CI, 0.893 to 1.277), 5.6 and 5.3 months (HR, 1.032; 95% CI, 0.866 to 1.231), and 22.8 and 24.5 months (HR, 1.038; 95% CI, 0.833 to 1.294), respectively (Fig 2) . Because the adjusted HR in PFS for gefitinib compared with erlotinib was not less than the noninferiority margin (HR, 1.30), this study did not meet the primary end point. The RRs for gefitinib versus erlotinib were 45.9% and 44.1%, respectively, and the DCRs were 70.9% and 75.3%, respectively (Table 2) . Planned subgroup analyses for PFS in the FAS revealed no statistically significant interaction of treatment, although a noticeable interaction effect of treatment with age was suggested ( Fig 3A) . However, the P value of the interaction test between age (, and $ 65 years) and treatment was not statistically significant (P = .065). The PFS and response of randomly sampled patients were reviewed externally, and the results showed the same trends as the original data.
At initiation of the study, EGFR mutation status was selected as one of the stratification factors. The EGFR mutation-positive Completed study Disease progression Discontinued due to toxicity Discontinued due to patient refusal Discontinued due to physician's decision Death during protocol treatment Other (n = 251) (n = 172) (n = 32) (n = 25) (n = 18) (n = 2) (n = 2)
Treated with gefitinib
Completed study Disease progression Discontinued due to toxicity Discontinued due to patient refusal Discontinued due to physician's decision Death during protocol treatment Other (n = 250) (n = 185) (n = 33) (n = 9) (n = 15) (n = 1) (n = 7) group consisted of patients with one of the major EGFR mutations (Ex19del or L858R). The EGFR mutation-negative group consisted of patients with wild-type EGFR or EGFR mutations other than Ex19del or L858R. After FAS data analysis, we checked every EGFR mutation status by original Case Report Form. Several patients displayed uncommon mutations or double mutations including T790M. To clarify the EGFR status and effect from each EGFR-TKI, we recategorized EGFR mutation status. Four hundred one of the patients displayed at least one kind of EGFR mutation. One hundred seventy-two patients displayed a single L858R mutation (gefitinib, n = 92; erlotinib, n = 80), and 192 patients displayed a single Ex19del mutation (gefitinib, n = 90; erlotinib, n = 102). Twelve patients displayed a double mutation (gefitinib, n = 6; erlotinib, n = 6), including three patients with L858R plus Ex19del, four patients with L858R plus an uncommon mutation, three patients with L858R plus T790M, one patient with Ex19del plus an uncommon mutation, and one patient with Ex19del plus T790M. Twenty-five patients displayed uncommon mutations. In the subset analysis, the EGFR mutation-positive group includes all patients with EGFR mutations, including common mutations, uncommon mutations, and double mutations. Median PFS, OS, RR, and DCR among patients in the gefitinib arm versus erlotinib arm with at least one kind of EGFR mutation were 8.3 and 10.0 months (HR, 1.093; 95% CI, 0.879 to 1.358; P = .424; Fig 4A) , 26.5 and 31.4 months (HR, 1.189; 95% CI, 0.900 to 1.570; P = .221; Appendix Fig A1, online only) , 58.9% and 55.0% (P = .476), and 81.7% and 84.4% (P = .517), respectively. Exploratory subset analysis of EGFR mutation restricted to Ex19del indicated that, for gefitinib versus erlotinib, the PFS, RR, and DCR were 11.1 and 11.5 months (HR, 1.120; 95% CI, 0.813 to 1.544; P = .487), 65.4% and 65.1% (P = .965), and 83.3% and 91.6% (P = .113), respectively. When restricted to L858R mutation, PFS, RR, and DCR for gefitinib versus erlotinib were 8.1 and 8.5 months (HR, 0.938; 95% CI, 0.675 to 1.304; P = .704), 57.5% and 46.3% (P = .174), and 81.3% and 79.1% (P = .744), respectively. In the subgroup with uncommon mutations (n = 25), median PFS, RR, and DCR for gefitinib versus erlotinib were 6. 4 (P = .419), and 66.7% and 71.4% (P = .829), respectively. In the subgroup with wild-type EGFR (n = 98), median PFS, RR, and DCR for gefitinib versus erlotinib were 2.0 and 1.7 months (HR, 1.270; 95% CI, 0.847 to 1.904; P = .241), 2.3% and 12.2% (P = .079), and 34.9% and 53.7% (P = .083), respectively (Table 2 , Figs 4B and 4D, Appendix Fig A2, online only) . In exploratory subset analysis of subgroups restricted to the EGFR mutations, subgroup analyses for PFS in the FAS revealed no statistically significant interaction of treatment, although a noticeable interaction effect of treatment with age was suggested (Fig 3B) . However, the P value of the interaction test between age (, and $ 65 years) and treatment was not statistically significant (P = .128) Toxicity Table 3 lists major toxicities. The incidence of grade 3 skin rash was lower in the gefitinib arm (2.2%) than the erlotinib arm (18.1%). The incidence of grade 3 or 4 increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) was 6.1% and 13.0% for gefitinib versus 2.2% and 3.3% for erlotinib, respectively. Liver function toxicity was more commonly observed in the gefitinib arm than the erlotinib arm. A 4% incidence of interstitial lung disease (ILD) was reported in each group, with three patients having grade 5 ILD in the erlotinib group. There were no significant differences between gefitinib and erlotinib in the incidence of any of the specific toxicity measures. Overall worst grade toxicity per patient (any toxicity) was computed, and the gefitinib arm showed a tendency toward significantly lower toxicity than the erlotinib arm (P , .001).
Met criteria and included in full analysis
Poststudy Treatment
Appendix Table A1 (online only) lists the poststudy treatment. Overall, 76.4% of the erlotinib arm and 78.5% of the gefitinib arm received poststudy treatment. There was no significant difference in the percentage of patients who received either an anticancer agent or radiation therapy after protocol treatment between the erlotinib and gefitinib arms. In the gefitinib arm, 17.2% of patients received another EGFR-TKI and 21.5% received the same EGFR-TKI. In the erlotinib arm, 10.0% of patients received another EGFR-TKI and 27.5% received the same EGFR-TKI.
DISCUSSION
To our knowledge, this is the first prospective randomized phase III study to directly compare two first-generation EGFRTKIs, gefitinib and erlotinib, in pretreated patients with lung Time ( adenocarcinoma. The outcome in our study did not satisfy the primary end point, which was noninferiority of gefitinib compared with erlotinib in terms of PFS among patients with lung adenocarcinoma. This study contains seven stratification factors. Many stratification factors may undermine the random assignment in a clinical trial (eg, loss of statistical power and validity of the statistical test). It may be more important, however, to assure the comparability between the treatment arms in terms of the critical prognostic or predictive factors, including institutions. Therefore, our study used a centralized dynamic random assignment method to minimize overstratification issues and achieve the betweengroup comparability in those many factors.
In Japan, gefitinib was approved in 2002 and had been widely and commonly used at the time of erlotinib's approval in 2007. In regard to adverse effects, gefitinib seemed to display milder adverse events than erlotinib; the cost of erlotinib is 1.5-fold the cost of gefitinib in Japan. On the basis of these factors, we established our trial as a noninferiority clinical trial.
One reason for the negative primary end point may be the underestimation in the trial design (ie, we based the estimation of PFS on the phase III ISEL 7 and BR.21 8 trials). The PFS for both EGFR-TKIs was, thus, estimated to be 2 to 4 months. However, the outcomes showed PFS times of 6.5 months (gefitinib arm) and 7.5 months (erlotinib arm). The estimation of sample size may have been too small to create a firm conclusion.
In 2008, when this study was planned, testing for EGFR mutation was neither common nor consistently conducted in Japan. 12 Numerous recent reports indicate a strong relationship between the effect of EGFR-TKIs and EGFR mutation, which lead us to focus our attention on the data for the EGFR mutationpositive population.
Our study included 401 EGFR mutation-positive patients (71.7% of FAS). Although only part of the subset analysis, we were able to conduct the largest prospective head-to-head trial comparing two EGFR-TKIs on EGFR mutation-positive patients to date. We divided the patients into the following subgroups: L858R only (n = 172), Ex19del only (n = 192), and uncommon mutations (n = 25). Regardless of the subgroup, analysis did not show any statistically significant differences in PFS between the gefitinib and erlotinib arms. The Ex19del subgroup showed numerically better PFS and response to EGFR-TKIs than the L858R mutation subgroup. It has already reported that erlotinib and afatinib tend to be more effective for patients with Ex19del than L858R. [13] [14] [15] [16] Previous reports concerning gefitinib treatment 9,10 cited no significant difference in PFS between Ex19del and L858R. In contrast, our data for gefitinib suggest that gefitinib also showed numerically better PFS for patients with Ex19del than L858R. This may indicate the need to distinguish between Ex19del and L858R populations when treating with EGFR-TKIs. Although the sample size was small for the EGFR wild-type population, the erlotinib arm indicated an RR of at least 10% even in second-line or later treatment. However, there was little response to gefitinib among the wild-type population.
At data cutoff, no difference was observed in terms of OS between gefitinib and erlotinib in both the FAS and the EGFR mutation-positive subgroup (Fig 2B, Appendix Fig A1) . Although these data were immature and this clinical trial was lacking in power to detect a significant difference in terms of OS, up-to-date OS results will be warranted.
Both drugs were well tolerated. The most common grade 3 or 4 toxicities in the erlotinib and gefitinib arms were rash and elevated ALT/AST, respectively. There was no significant difference in the incidence of ILD regardless of grade. The results were based on direct comparison between erlotinib and gefitinib, and the data are consistent with previous data from evaluations of each EGFR-TKI. 9, 10, 14, 15 In conclusion, our study was unable to demonstrate statistical noninferiority in PFS between erlotinib and gefitinib. Subset analysis including mutation status did not reveal any populations with noteworthy differences in clinical efficacy between gefitinib and erlotinib. This suggests that, although not demonstrated to be statistically noninferior, gefitinib could be therapeutic option, considering the milder adverse effects in patients with EGFR mutation-positive adenocarcinoma.
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Progression-free survival was defined as the time from the date of random assignment to the earliest sign of disease progression, determined according to RECIST or death as a result of any cause. Patients without documented death or progression or for whom the exact date of the event was unknown at the time of analysis were censored on the last date known to be alive. Overall survival was defined as the time from date of enrollment until death from any cause. Patients alive at the time of analysis were censored on the last confirmed date of survival. Time to treatment failure was defined as the time from the date of enrollment to the date of treatment termination. Response rate was defined as the proportion of eligible patients with measurable lesions who achieved an overall response of confirmed complete response/remission or partial response/remission. The disease control rate was defined as the proportion of patients who achieved a confirmed complete response, partial response, or stable disease. 
